Stock listing

Newron Pharmaceuticals S.p.a.

Selected listing: NP5 · XETR · EUR · DE

Newron Pharmaceuticals S.p.a. (Xetra:NP5), Health Technology. Latest release Sep 22, 2026: Newron presents H1 2026 results and provides corporate update.

NP5:XETREURDEUpdated October 2, 2026

Ticker: Xetra:NP5
Asset type: Stock
Sector: Health Technology
Industry: Pharmaceuticals: Major
Exchange: Xetra
Currency: EUR

About Newron Pharmaceuticals S.p.a.

The company focuses on developing innovative treatments for patients with neurological diseases. Newron is committed to advancing its pipeline of therapies to address unmet medical needs in this specialized field.

Latest news from Newron Pharmaceuticals S.p.a.

Newron presents H1 2026 results and provides corporate update

September 22, 2026

Newron Pharmaceuticals S p A : presents H1 2026 results and provides corporate update

September 22, 2026

Newron Reports Subscription for EUR 5.5 Million of Shares by Investor Group as Part of Up to EUR 38 Million Total Financing to Advance Phase 3 Evenamide Program

September 8, 2026

Newron Pharmaceuticals to Participate in H.C. Wainwright 28th Annual Global Investment Conference

September 3, 2026

Newron announces completion of screening for enrollment in pivotal Phase 3 ENIGMA-TRS 1 study with evenamide as add-on therapy in patients with treatment-resistant schizophrenia (TRS)

September 2, 2026

All Newron Pharmaceuticals S.p.a. news →

Events

Replays

Newron Pharmaceuticals S.p.A. (0QOI) Q4 2025 Earnings Call
Tue, Mar 24, 2026 · 09:30 AM ET
Watch

Research Newron Pharmaceuticals S.p.a.

Newron Pharmaceuticals S.p.a. company profile

View the public company page for Newron Pharmaceuticals S.p.a. on 6ix.

Newron Pharmaceuticals S.p.a. news

Read company news and market updates connected to Newron Pharmaceuticals S.p.a..

Newron Pharmaceuticals S.p.a. investor events

Find investor webinars, events, and replay context for Newron Pharmaceuticals S.p.a..